Matrubials, Inc.

Roseville, CA · Biotech · Private

HBCA2, an antimicrobial peptide derived from human milk casein, formulated as a selective topical therapeutic for bacterial vaginosis treatment.

Grants
$287K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
5
0 granted · 5 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Selective antimicrobial peptides from milk for bacterial vaginosis$286,968
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1211AUGMENTA BIOWORKS, INC.——
1212Dianomi Therapeutics, Inc.—$185K
1213Novoglia, Inc.—$37M
1214Matrubials, Inc.——
1215MADRIGAL PHARMACEUTICALS, INC.—$35M
1216OS Therapies Inc—$30M
1217Universal Ibogaine Inc.—$135K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 5
  • Mammalian Milk-derived Peptides With Antimicrobial Activityapplication
  • Milk Peptide Compositions For Pharmaceutical And Cosmeceutical Useapplication
  • Milk Peptide Compositions For Pharmaceutical And Cosmeceutical Useapplication
  • Mammalian Milk-derived Peptides With Antimicrobial Activityapplication
  • Mammalian Milk-derived Peptides With Antimicrobial Activityapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.